PMID- 23733001
OWN - NLM
STAT- MEDLINE
DCOM- 20140509
LR  - 20211021
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 19
IP  - 8
DP  - 2013 Aug
TI  - Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell 
      transplantation in multiple myeloma.
PG  - 1227-32
LID - S1083-8791(13)00230-9 [pii]
LID - 10.1016/j.bbmt.2013.05.017 [doi]
AB  - The t(11;14)(q13;q32) translocation is seen in 15%-20% patients with multiple 
      myeloma (MM). It generally is not associated with worse outcomes. We studied the 
      impact of t(11;14)(q13;q32) on outcome in patients with MM who received high-dose 
      chemotherapy followed by autologous hematopoietic stem cell transplantation 
      (auto-HCT). Eligible patients underwent high-dose chemotherapy followed by 
      auto-HCT at the M.D. Anderson Cancer Center between February 2000 and August 
      2010, and had conventional cytogenetic (CC) or fluorescence in situ hybridization 
      (FISH) results available before auto-HCT (n = 993). The cohort was divided into 3 
      groups of patients: (1) normal (diploid by CC and negative by FISH; n = 869); (2) 
      t(11;14)(q13;q32) by CC or FISH (n = 27); and (3) high-risk (HR) abnormalities by 
      CC or FISH (n = 97). Of the 27 patients with t(11;14)(q13;q32), 18 had isolated 
      t(11;14)(q13;q32) and 9 had concurrent HR abnormalities. The primary objective 
      was to compare outcomes in patients with t(11;14)(q13;q32) and patients with 
      diploid or HR markers detected by CC or FISH studies. The median duration of 
      follow-up in surviving patients was 37 months. The 3-year progression-free 
      survival (PFS) was 47% for the normal group, 27% for the t(11;14)(q13;q32) group, 
      and 13% for the HR group (P < .00001). The 3-year OS was 83% for the normal 
      group, 63% for the t(11;14)(q13;q32) group, and 34% for the HR group 
      (P < .00001). On multivariate analysis, t(11;14)(q13;q32) and HR abnormalities by 
      CC or FISH and relapsed disease at auto-HCT were associated with shorter PFS, 
      whereas t(11;14)(q13;q32) and HR abnormalities by CC or FISH, beta2 microglobulin of 
      >3.5, and relapsed disease at the time of auto-HCT were associated with shorter 
      OS. In conclusion, patients with t(11;14)(q13;q32) had worse outcomes than 
      patients with normal CC or FISH studies, but better outcomes than patients with 
      HR markers detected by CC or FISH studies.
CI  - Copyright (c) 2013 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Sasaki, Koji
AU  - Sasaki K
AD  - Department of Medicine, Beth Israel Medical Center, New York, NY 10003, USA. 
      koji_1225shasha@yahoo.co.jp
FAU - Lu, Gary
AU  - Lu G
FAU - Saliba, Rima M
AU  - Saliba RM
FAU - Bashir, Qaiser
AU  - Bashir Q
FAU - Hosing, Chitra
AU  - Hosing C
FAU - Popat, Uday
AU  - Popat U
FAU - Shah, Nina
AU  - Shah N
FAU - Parmar, Simrit
AU  - Parmar S
FAU - Dinh, Yvonne
AU  - Dinh Y
FAU - Ahmed, Sairah
AU  - Ahmed S
FAU - Shpall, Elizabeth J
AU  - Shpall EJ
FAU - Kebriaei, Partow
AU  - Kebriaei P
FAU - Shah, Jatin J
AU  - Shah JJ
FAU - Orlowski, Robert Z
AU  - Orlowski RZ
FAU - Champlin, Richard
AU  - Champlin R
FAU - Qazilbash, Muzaffar H
AU  - Qazilbash MH
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA142509/CA/NCI NIH HHS/United States
GR  - U10 CA032102/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 14
MH  - Cytogenetics
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics/immunology/*surgery
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Translocation, Genetic
MH  - Transplantation, Autologous
MH  - Treatment Outcome
PMC - PMC4150684
MID - NIHMS619376
OTO - NOTNLM
OT  - Autologous transplantation
OT  - Cytogenetics
OT  - Myeloma
OT  - t(11;14)
EDAT- 2013/06/05 06:00
MHDA- 2014/05/10 06:00
PMCR- 2014/09/01
CRDT- 2013/06/05 06:00
PHST- 2013/01/23 00:00 [received]
PHST- 2013/05/22 00:00 [accepted]
PHST- 2013/06/05 06:00 [entrez]
PHST- 2013/06/05 06:00 [pubmed]
PHST- 2014/05/10 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - S1083-8791(13)00230-9 [pii]
AID - 10.1016/j.bbmt.2013.05.017 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32. doi: 
      10.1016/j.bbmt.2013.05.017. Epub 2013 May 31.